Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 77 results for psoriasis

  1. Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease control i) safely; ii) effectively and iii) what are the health economic implications? 2. What are the risks of 'real life' long term corticosteroid use, are there particular people at risk and what strategies can be used to modify or avoid risks?

    CG153/5 Question Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease...

    Research recommendation
    Published
    9 June 2015

  2. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  5. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  9. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  10. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  11. Tofacitinib for treating juvenile idiopathic arthritis (TA735)

    Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.

    Technology appraisal guidance
    Published
    20 October 2021
    View recommendations

    Sections for TA735

  12. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  13. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  14. Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.

    Technology appraisal guidance
    Published
    21 July 2021
    View recommendations

    Sections for TA719

  15. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021